Author
Mehmet Yilmaz
Other affiliations: University of Gaziantep, Paris Diderot University, Eskişehir Osmangazi University ...read more
Bio: Mehmet Yilmaz is an academic researcher from Dokuz Eylül University. The author has contributed to research in topics: Heart failure & Medicine. The author has an hindex of 40, co-authored 618 publications receiving 8292 citations. Previous affiliations of Mehmet Yilmaz include University of Gaziantep & Paris Diderot University.
Papers published on a yearly basis
Papers
More filters
University of Helsinki1, French Institute of Health and Medical Research2, Paris Diderot University3, Vilnius University4, University of Zurich5, Centro Nacional de Investigaciones Cardiovasculares6, Complutense University of Madrid7, Athens State University8, Imperial College London9, University of Porto10, University of Barcelona11, University Hospital of Basel12, University of Hasselt13, Free University of Brussels14, VU University Amsterdam15, St George's, University of London16, Vita-Salute San Raffaele University17, Cumhuriyet University18, Democritus University of Thrace19
TL;DR: In the setting of either pressure overload or volume overload, the right ventricular mechanics and function are altered and the RV chamber becomes more spherical and tricuspid regurgitation is aggravated, a cascade leading to increasing venous congestion as mentioned in this paper.
Abstract: Acute right ventricular (RV) failure is a complex clinical syndrome that results from many causes. Research efforts have disproportionately focused on the failing left ventricle, but recently the need has been recognized to achieve a more comprehensive understanding of RV anatomy, physiology, and pathophysiology, and of management approaches. Right ventricular mechanics and function are altered in the setting of either pressure overload or volume overload. Failure may also result from a primary reduction of myocardial contractility owing to ischaemia, cardiomyopathy, or arrhythmia. Dysfunction leads to impaired RV filling and increased right atrial pressures. As dysfunction progresses to overt RV failure, the RV chamber becomes more spherical and tricuspid regurgitation is aggravated, a cascade leading to increasing venous congestion. Ventricular interdependence results in impaired left ventricular filling, a decrease in left ventricular stroke volume, and ultimately low cardiac output and cardiogenic shock. Identification and treatment of the underlying cause of RV failure, such as acute pulmonary embolism, acute respiratory distress syndrome, acute decompensation of chronic pulmonary hypertension, RV infarction, or arrhythmia, is the primary management strategy. Judicious fluid management, use of inotropes and vasopressors, assist devices, and a strategy focusing on RV protection for mechanical ventilation if required all play a role in the clinical care of these patients. Future research should aim to address the remaining areas of uncertainty which result from the complexity of RV haemodynamics and lack of conclusive evidence regarding RV-specific treatment approaches.
433 citations
University of California1, Duke University2, University of Glasgow3, University of Brescia4, Harvard University5, University of North Carolina at Chapel Hill6, University of Minnesota7, University of Copenhagen8, Saarland University9, Medical University of Vienna10, Imperial College London11, Pontifical Catholic University of Chile12, Linköping University13, University of Utah14, National and Kapodistrian University of Athens15, Nova Southeastern University16, Comenius University in Bratislava17, Sofia Medical University18, Henry Ford Hospital19, Peking Union Medical College20, Middlemore Hospital21, St. Vincent's Health System22, Moscow State University23, Université de Montréal24, Wrocław Medical University25, University of São Paulo26, Vilnius University27, University of Cape Town28, Masaryk University29, University Hospital of Bern30, St John of God Health Care31, Carol Davila University of Medicine and Pharmacy32, University of Groningen33, Dokuz Eylül University34, University of Lorraine35, Amgen36
TL;DR: Among patients with heart failure and a reduced ejection, patients who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo.
Abstract: Background The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect ...
341 citations
University of Debrecen1, Ghent University Hospital2, University of Helsinki3, University of Paris4, Vita-Salute San Raffaele University5, University of the East6, Sapienza University of Rome7, University of Hamburg8, Lund University9, Sahlgrenska University Hospital10, Hospital Universitario de Canarias11, Cumhuriyet University12, Orion Corporation13, University of Zurich14
TL;DR: The data indicate that the cardiovascular effects of levosimendan are exerted via more than an isolated drug-receptor interaction, and involve favorable energetic and neurohormonal changes that are unique in comparison to other types of inodilators.
256 citations
Helsinki University Central Hospital1, University of Hasselt2, Hannover Medical School3, Carol Davila University of Medicine and Pharmacy4, Vanderbilt University5, Humboldt University of Berlin6, National and Kapodistrian University of Athens7, University of Zurich8, University of Hamburg9, University of Ljubljana10, University of Paris11, Chartered Institute of Management Accountants12, University of Basel13, University of Debrecen14, Harvard University15, University of Belgrade16, American University of Beirut17, Cumhuriyet University18
TL;DR: The prevention and correction of organ dysfunction represent a therapeutic target of interest in AHF and should be evaluated in clinical trials to determine if such interventions impact mortality, morbidity and patient‐centred outcomes.
Abstract: Organ injury and impairment are commonly observed in patients with acute heart failure (AHF), and congestion is an essential pathophysiological mechanism of impaired organ function Congestion is the predominant clinical profile in most patients with AHF; a smaller proportion presents with peripheral hypoperfusion or cardiogenic shock Hypoperfusion further deteriorates organ function The injury and dysfunction of target organs (ie heart, lungs, kidneys, liver, intestine, brain) in the setting of AHF are associated with increased risk for mortality Improvement in organ function after decongestive therapies has been associated with a lower risk for post-discharge mortality Thus, the prevention and correction of organ dysfunction represent a therapeutic target of interest in AHF and should be evaluated in clinical trials Treatment strategies that specifically prevent, reduce or reverse organ dysfunction remain to be identified and evaluated to determine if such interventions impact mortality, morbidity and patient-centred outcomes This paper reflects current understanding among experts of the presentation and management of organ impairment in AHF and suggests priorities for future research to advance the field
241 citations
Utrecht University1, VU University Medical Center2, Erasmus University Rotterdam3, Leiden University4, University of Amsterdam5, University Medical Center Groningen6, Leiden University Medical Center7, Flanders Institute for Biotechnology8, Radboud University Nijmegen9, Netherlands Cancer Institute10, Erasmus University Medical Center11
TL;DR: Target locus amplification (TLA) is presented, a strategy to selectively amplify and sequence entire genes on the basis of the crosslinking of physically proximal sequences that enables robust detection of single nucleotide variants, structural variants and gene fusions in clinically relevant genes, and enables haplotyping.
Abstract: Despite developments in targeted gene sequencing and whole-genome analysis techniques, the robust detection of all genetic variation, including structural variants, in and around genes of interest and in an allele-specific manner remains a challenge. Here we present targeted locus amplification (TLA), a strategy to selectively amplify and sequence entire genes on the basis of the crosslinking of physically proximal sequences. We show that, unlike other targeted re-sequencing methods, TLA works without detailed prior locus information, as one or a few primer pairs are sufficient for sequencing tens to hundreds of kilobases of surrounding DNA. This enables robust detection of single nucleotide variants, structural variants and gene fusions in clinically relevant genes, including BRCA1 and BRCA2, and enables haplotyping. We show that TLA can also be used to uncover insertion sites and sequences of integrated transgenes and viruses. TLA therefore promises to be a useful method in genetic research and diagnostics when comprehensive or allele-specific genetic information is needed.
228 citations
Cited by
More filters
TL;DR: Authors/Task Force Members: Piotr Ponikowski* (Chairperson) (Poland), Adriaan A. Voors* (Co-Chair person) (The Netherlands), Stefan D. Anker (Germany), Héctor Bueno (Spain), John G. F. Cleland (UK), Andrew J. S. Coats (UK)
13,400 citations
TL;DR: ACCF/AHAIAI: angiotensin-converting enzyme inhibitor as discussed by the authors, angio-catabolizing enzyme inhibitor inhibitor inhibitor (ACS inhibitor) is a drug that is used to prevent atrial fibrillation.
Abstract: ACC/AHA
: American College of Cardiology/American Heart Association
ACCF/AHA
: American College of Cardiology Foundation/American Heart Association
ACE
: angiotensin-converting enzyme
ACEI
: angiotensin-converting enzyme inhibitor
ACS
: acute coronary syndrome
AF
: atrial fibrillation
7,489 citations
TL;DR: Authors/Task Force Members: Piotr Ponikowski* (Chairperson) (Poland), Adriaan A. Voors* (Co-Chair person) (The Netherlands), Stefan D. Anker (Germany), Héctor Bueno (Spain), John G. F. Cleland (UK), Andrew J. S. Coats (UK)
Abstract: ACC/AHA
: American College of Cardiology/American Heart Association
ACCF/AHA
: American College of Cardiology Foundation/American Heart Association
ACE
: angiotensin-converting enzyme
ACEI
: angiotensin-converting enzyme inhibitor
ACS
: acute coronary syndrome
AF
: atrial fibrillation
6,757 citations
TL;DR: 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation are published.
Abstract: 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)
6,599 citations
Book•
01 Jan 1979
5,044 citations